Loading
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Regular session
$26.80
+$0.93 · +3.59%
Regular session · ET · Market data may be delayed.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Day range
Current $26.80
52-week range
Current $26.80
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
31
Expensive
Sentiment
63
Bullish
Risk
57
Elevated Risk
Momentum
80
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Day range
Current $26.80
52-week range
Current $26.80
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 925K USD | — | — | — |
| Cost of goods sold | 3.19M USD | 3.25M USD | 3.26M USD | 3.2M USD | 42.26M USD |
| Gross profit | −3.19M USD | −2.32M USD | −3.26M USD | −3.2M USD | −42.26M USD |
| Research and development | 75.01M USD | 60.92M USD | 44.39M USD | 47.51M USD | 42.26M USD |
| Selling, general, and administrative | 25.13M USD | 22.61M USD | 11.19M USD | 9.01M USD | 8.27M USD |
| Operating expenses | 100.02M USD | 80.28M USD | 52.32M USD | 53.32M USD | 8.27M USD |
| Interest income | 11.55M USD | 8.47M USD | 2.95M USD | 1.34M USD | 19K USD |
| Interest expense | 5K USD | 12K USD | 12K USD | 2K USD | — |
| Depreciation and amortization | 3.09M USD | 3.25M USD | 3.3M USD | 3.2M USD | 947K USD |
| Operating income | −103.21M USD | −82.61M USD | −55.58M USD | −56.52M USD | −50.53M USD |
| Net income | −90.35M USD | −75.14M USD | −36.32M USD | −55.19M USD | −50.52M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$72.00
168.66% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 19, 2023 | 1:4 | — | — |
Stock split | Sep 25, 2023 | 1:5 | — | — |
Effective Dec 19, 2023
1:4
Effective Sep 25, 2023
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM10.59M0.01%78.56B USD0.19%$277.07-0.23%
State Street SPDR S&P Biotech ETFXBI7.1M0.07%10.08B USD0.35%$148.65-1.05%
iShares Biotechnology ETFIBB3.12M0.03%10.4B USD0.44%$199.61-1.83%
Fidelity Enhanced Small Cap ETFFESM2.77M0.04%6.41B USD0.28%$45.125-0.21%
Vanguard Russell 2000 ETFVTWO2.36M0.01%18B USD0.06%$111.89-0.29%
iShares Micro-Cap ETFIWC1.27M0.10%1.33B USD0.60%$182.36-0.55%
Vanguard Health Care ETFVHT1.14M0.01%22B USD0.09%$312.23-0.98%
Avantis U.S. Small Cap Equity ETFAVSC753.05K0.02%3.04B USD0.25%$69.975+0.50%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
